Meta-analysis of the effects of statin therapy on endothelial function in patients with diabetes mellitus

Atherosclerosis

Volumn 223, Issue 1, 2012, Pages 78-85

  Zhang, Lin ^a   Gong, DingXu ^a   Li, ShaoHua ^b   Zhou, XianLiang ^a  

^a FUWAI HOSPITAL   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Diabetes mellitus; Meta analysis; Obesity; Statin therapy

Indexed keywords

ATORVASTATIN; CERIVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

AGE; BLOOD PRESSURE; BODY MASS; COCHRANE LIBRARY; DIABETES MELLITUS; DRUG MECHANISM; EMBASE; ENDOTHELIAL DYSFUNCTION; HIGH RISK POPULATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIPID BLOOD LEVEL; MEDLINE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; RECOVERY OF FUNCTION; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; VASODILATION;

EID: 84863083723     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.01.031     Document Type: Review

References (44)

1. Wild S., Roglic G., Green A., et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
2. Nesto R.W. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Am J Cardiovasc Drugs 2005, 5:379-387.
3. Meyers M.R., Gokce N. Endothelial dysfunction in obesity: etiological role in atherosclerosis. Curr Opin Endocrinol Diabetes Obes 2007, 14:365-369.
4. Pirro M., Bagaglia F., Paoletti L., et al. Hypercholesterolemia-associated endothelial progenitor cell dysfunction. Ther Adv Cardiovasc Dis 2008, 2:329-339.
5. de Sotomayor M.A., Perez-Guerrero C., Herrrera M.D., et al. Improvement of age-related endothelial dysfunction by simvastatin: effect on NO and COX pathways. Br J Pharmacol 2005, 146:1130-1138.
6. Endres M., Laufs U., Huang Z., et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998, 95:8880-8885.
7. Ridker P.M., Rifai N., Pfeffer M.A., et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999, 100:230-235.
8. Balletshofer B.M., Goebbel S., Rittig K., et al. Intense cholesterol lowering therapy with a HMG-CoA reductase inhibitor does not improve nitric oxide dependent endothelial function in type-2-diabetes-a multicenter, randomised, double-blind, three-arm placebo-controlled clinical trial. Exp Clin Endocrinol Diabetes 2005, 113:324-330.
9. Beishuizen E.D., Tamsma J.T., Jukema J.W., et al. The effect of statin therapy on endothelial function in type 2 diabetes without manifest cardiovascular disease. Diabetes Care 2005, 28:1668-1674.
10. Dogra G.K., Watts G.F., Chan D.C., et al. Statin therapy improves brachial artery vasodilator function in patients with Type 1 diabetes and microalbuminuria. Diabet Med 2005, 22:239-242.
11. Economides P.A., Caselli A., Tiani E., et al. The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. J Clin Endocrinol Metab 2004, 89:740-747.
12. Konduracka E., Galicka-Latala D., Cieslik G., et al. Effect of atorvastatin on endothelial function and inflammation in long-duration type 1 diabetic patients without coronary heart disease and arterial hypertension. Diabetes Obes Metab 2008, 10:719-725.
13. Corretti M.C., Anderson T.J., Benjamin E.J., et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002, 39:257-265.
14. Moher D., Cook D.J., Eastwood S., et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 1999, 354:1896-1900.
15. Moher D., Pham B., Jones A., et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998, 352:609-613.
16. Follmann D., Elliott P., Suh I., et al. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 1992, 45:769-773.
17. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
18. Egger M., Davey Smith G., Schneider M., et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
19. Koh K.K., Son J.W., Ahn J.Y., et al. Simvastatin combined with ramipril treatment in hypercholesterolemic patients. Hypertension 2004, 44:180-185.
20. Ceriello A., Taboga C., Tonutti L., et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 2002, 106:1211-1218.
21. Paniagua J.A., Lopez-Miranda J., Perez-Martinez P., et al. Oxidized-LDL levels are changed during short-term serum glucose variations and lowered with statin treatment in early type 2 diabetes: a study of endothelial function and microalbuminuria. Diabet Med 2005, 22:1647-1656.
22. Tsunekawa T., Hayashi T., Kano H., et al. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001, 104:376-379.
23. Koh K.K., Quon M.J., Han S.H., et al. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension 2005, 45:1088-1093.
24. Mullen M.J., Wright D., Donald A.E., et al. Atorvastatin but not l-arginine improves endothelial function in type I diabetes mellitus: a double-blind study. J Am Coll Cardiol 2000, 36:410-416.
25. Tantikosoom W., Thinkhamrop B., Kiatchusakul S., et al. Randomized trial of atorvastatin in improving endothelial function in diabetics without prior coronary disease and having average cholesterol level. J Med Assoc Thai 2005, 88:399-406.
26. van Venrooij F.V., van de Ree M.A., Bots M.L., et al. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial. Diabetes Care 2002, 25:1211-1216.
27. Casino P.R., Kilcoyne C.M., Quyyumi A.A., et al. The role of nitric oxide in endothelium-dependent vasodilation of hypercholesterolemic patients. Circulation 1993, 88:2541-2547.
28. Masumoto A., Hirooka Y., Hironaga K., et al. Effect of pravastatin on endothelial function in patients with coronary artery disease (cholesterol-independent effect of pravastatin). Am J Cardiol 2001, 88:1291-1294.
29. Hadi H.A., Suwaidi J.A. Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag 2007, 3:853-876.
30. Athyros V.G., Kakafika A.I., Tziomalos K., et al. Pleiotropic effects of statins-clinical evidence. Curr Pharm Des 2009, 15:479-489.
31. Apovian C.M., Bigornia S., Mott M., et al. Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler Thromb Vasc Biol 2008, 28:1654-1659.
32. Nishimura S., Manabe I., Nagasaki M., et al. In vivo imaging in mice reveals local cell dynamics and inflammation in obese adipose tissue. J Clin Invest 2008, 118:710-721.
33. Doupis J., Rahangdale S., Gnardellis C., et al. Effects of diabetes and obesity on vascular reactivity, inflammatory cytokines, and growth factors. Obesity (Silver Spring) 2011, 19:729-735.
34. Taddei S., Virdis A., Ghiadoni L., et al. Age-related reduction of NO availability and oxidative stress in humans. Hypertension 2001, 38:274-279.
35. Panza J.A., Casino P.R., Kilcoyne C.M., et al. Impaired endothelium-dependent vasodilation in patients with essential hypertension: evidence that the abnormality is not at the muscarinic receptor level. J Am Coll Cardiol 1994, 23:1610-1616.
36. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696.
37. Witte D.R., Westerink J., de Koning E.J., et al. Is the association between flow-mediated dilation and cardiovascular risk limited to low-risk populations?. J Am Coll Cardiol 2005, 45:1987-1993.
38. Lusis A.J. Atherosclerosis. Nature 2000, 407:233-241.
39. Benetos A., Waeber B., Izzo J., et al. Influence of age, risk factors, and cardiovascular and renal disease on arterial stiffness: clinical applications. Am J Hypertens 2002, 15:1101-1108.
40. Dupuis J., Tardif J.C., Cernacek P., et al. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999, 99:3227-3233.
41. Fleg J.L., Mete M., Howard B.V., et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol 2008, 52:2198-2205.
42. Sheu W.H., Juang B.L., Chen Y.T., et al. Endothelial dysfunction is not reversed by simvastatin treatment in type 2 diabetic patients with hypercholesterolemia. Diabetes Care 1999, 22:1224-1225.
43. Bigornia S.J., Mott M.M., Hess D.T., et al. Long-term successful weight loss improves vascular endothelial function in severely obese individuals. Obesity (Silver Spring) 2010, 18:754-759.
44. Tan K.C., Chow W.S., Tam S.C., et al. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab 2002, 87:563-568.